Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSC000190
- Development stage
- Unknown
- Lead developer
- Changchun GeneScience Pharmaceutical
01
Overview
GSC000190: sourced facts only. name: "In vitro, GSC000190 inhibited KIF18A ATPase activity with a single nM potency and has great potency inhibiting growth of a wide range of TP53 mutant/CIN+ tumor cells." [DOI:10.1158/1538-7445.am2024-664]; target: "In vitro, GSC000190 inhibited KIF18A ATPase activity with a single nM potency and has great potency inhibiting growth of a wide range of TP53 mutant/CIN+ tumor cells." [DOI:10.1158/1538-7445.am2024-664]; developer: "1Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2024-664]; stage: "In an HGSOC PDX model which is resistant to platinum and olaparib, GSC000190 induced strong tumor regression both as single agent and through combination without significant body weight reduction." [DOI:10.1158/1538-7445.am2024-664]
02
Targets
KIF18A (Kinesin family member 18A)
Beyond the preview
Go deeper on GSC000190.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSC000190.